{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0000495\nAge: 49\nGender: Female\nSample ID: P-0000495-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Breast Invasive Ductal Carcinoma\nSample Type: Metastasis\nTumor Purity: 30.0%\n=============\nDNA Variants:\nAXL c.2557A>T (p.S853C) - in 9.00% of 633 reads\nBRCA1 c.4705A>G (p.S1569G) - in 8.00% of 471 reads\nFOXL2 c.458T>C (p.F153S) - in 9.00% of 175 reads\nIKZF1 c.277A>C (p.N93H) - in 7.00% of 512 reads\nNOTCH1 c.5734G>A (p.D1912N) - in 6.00% of 673 reads\nPIK3CA c.3140A>G (p.H1047R) - in 45.00% of 776 reads\nPTPRS c.4381T>A (p.Y1461N) - in 17.00% of 507 reads\nRICTOR c.1441G>A (p.E481K) - in 11.00% of 870 reads\nTP53 c.949delC (p.Q317Sfs*28) - in 29.00% of 421 reads\nU2AF1 c.508A>T (p.N170Y) - in 12.00% of 556 reads\nCNA Data:\nAXIN2 - High Level Amplification\nAURKA - High Level Amplification\nFOXA1 - High Level Amplification\nGNAS - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    \n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Solid Tumor with high tumor mutational burden (TMB-H)\",\n    \"Disease Phase or Condition\": \"Unresectable or metastatic solid tumor\",\n    \"Drug Name\": \"Pembrolizumab\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment; no satisfactory alternative treatment options\",\n    \"Genomic Features\": \"TMB-H (>=10 mutations/Mb)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Low-Grade Serous Ovarian Cancer\",\n    \"Disease Phase or Condition\": \"Recurrent, KRAS-mutated\",\n    \"Drug Name\": \"Avutometinib + Defactinib\",\n    \"Prior Treatment or Resistance Status\": \"Received prior systemic therapy\",\n    \"Genomic Features\": \"KRAS p.G12V mutation\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf\"\n  }\n}"
}